GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
4.6k
c/trialwatch·posted 2 years ago by u/camila_vasquez

SELECT is the most under-discussed thing in c/bloodwork

Trial Data Clean Column ×9 Cold Box ×1 Long Haul ×2

Quick one. Canada here.

endpoint works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US.

Specifics: the route I used took 6 weeks and cost roughly what I expected. The admin was worse than the cost. The thing that would have saved me the most time was knowing which document to ask for at the start.

Happy to answer questions from anyone in the same jurisdiction.

5,287 up / 724 down88% upvoted58 commentsid 15uz4112 Dec 2023

58 comments

22 in this archive, depth 5

best — the order this archive was captured in

u/trialwatch_theoMOD657 points·2 years ago

Flair changed to match the content. Read the sidebar before posting next time and we are square.

replysharereportpermalink
u/hazard_ratio_halstats279 points·2 years ago·edited

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

replysharereportpermalink
u/camila_vasquez260 points·2 years ago

Is that absolute or relative risk reduction?

replysharereportpermalink
u/camila_vasquezOP138 points·2 years ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/camila_vasquezOP-13 points·2 years ago

Phase 2 or phase 3?

replysharereportpermalink
u/kaia_cabrera-17 points·2 years ago

number-needed-to-treat is the house dialect

replysharereportpermalink
u/injection_site_iris439 points·2 years ago

the discontinuation arms are the interesting part, not the endpoint endpoints

replysharereportpermalink
u/enzo_ferrari328 points·2 years ago

Mechanistically the bit that matters is TRIUMPH. It explains most of the early profile and a decent chunk of the outcome.

replysharereportpermalink
u/joaquin_stanescu102 points·2 years ago·edited

What was the dropout rate?

replysharereportpermalink
u/annika_fonseca54 points·2 years ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/ewan_tulloch256 points·2 years ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/camila_vasquezOP146 points·2 years ago

STEP 1 readout: 99.3% mean weight loss, absolute numbers matter. Spread around that mean is enormous.

replysharereportpermalink
u/cold_chromatogram3141 points·2 years ago

STEP 1 readout: 99.3% mean weight loss, absolute numbers matter.

Disagree on that part. 98.4% and 98.3% on the same vial is normal.

replysharereportpermalink
u/ferran_dahlberg87 points·2 years ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
[deleted]36 points·2 years ago

[deleted]

replysharereportpermalink
u/tove_ogunleye57 points·2 years ago

the relative risk reduction in headlines is not the whole story

Adding to this: SELECT is doing more work than the comment implies.

replysharereportpermalink
u/nightowl_injector95 points·2 years ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/sanne_laurent68 points·2 years ago

Small correction: the trial was 16 weeks, not 15. Does not change your point but people will quote it.

replysharereportpermalink
u/careful_gradient_again71 points·2 years ago

Small correction: the trial was 15 weeks, not 21. Does not change your point but people will quote it.

replysharereportpermalink
u/alcohol_aversion192 points·2 years ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
u/cloudy_vial_carol123 points·2 years ago

off-label use data is different from approved-indication data

replysharereportpermalink
u/formulary_fighterappeals75 points·2 years ago·edited

Sceptical. If this were true we would see it reflected in the data and we do not.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.